HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewis, J. W. Articles by Magilligan, D. J. Search for Related Content PubMed PubMed Citation Articles by Lewis, J. W., Jr Articles by Magilligan, D. J., Jr

The Annals of Thoracic Surgery, Vol 49, 728-732, Copyright © 1990 by The Society of Thoracic Surgeons

ARTICLES

Role of brachytherapy in the management of pulmonary and mediastinal malignancies

JW Lewis Jr, M Ajlouni, PA Kvale, N Groux, Y Bae, BS Horowitz and DJ Magilligan Jr
Division of Thoracic and Cardiac Surgery, Henry Ford Hospital, Detroit, Michigan 48202.

Brachytherapy, the permanent or temporary implantation of radioactive sources, has been performed in limited numbers of patients with lung cancer over the last 50 years. Because of renewed interest in this modality, we reviewed our experience with 103 patients treated over a 7- year period. The mean age of this group was 55.5 years (range, 1 to 84 years). Primary lung cancer accounted for 82 patients (79.6%); metastatic lesions to the lung, 13 (12.6%); and mediastinal malignancies, 8 (7.8%). Indications for brachytherapy included mediastinal and chest wall invasion in 42 patients (40.8%), unresectable tumors and mediastinal adenopathy in 30 (29.1%), medical contraindications to extensive pulmonary resection in 20 (19.4%), and irradiation of excised lymph node beds in 11 (10.7%). Seeds labeled with radioactive iodine 125 alone were used in 65 patients (63.1%), afterloading catheters containing iridium 192 sources in 25 (24.3%), and both in 13 (12.6%). There were no operative deaths. With a mean follow-up of 18.6 months, the mean and median survivals for the entire group were 17.3 and 14.0 months, respectively. The 1-year, 2-year, and 3-year survivals for the entire group were 67.9%, 38.7%, and 27.8%, respectively. In summary, brachytherapy offers a useful surgical approach in patients in whom unresectable pulmonary or mediastinal malignancies are found at the time of thoracotomy or in patients previously treated with other modalities for whom limited therapeutic alternatives exist.

This article has been cited by other articles:

				W. Lee, B. D.T. Daly, T. A. DiPetrillo, D. M. Morelli, A. C. Neuschatz, J. Morr, and M. J. Rivard Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds Ann. Thorac. Surg., January 1, 2003; 75(1): 237 - 242. [Abstract] [Full Text] [PDF]